Orion Corporation, co-developer of the prostate-cancer therapy darolutamide (marketed by Bayer as Nubeqa®), has forecast that annual net sales recorded by Orion—including tablet sales to Bayer plus royalties—could exceed EUR 1 billion by the end of the decade. This projection follows rapid uptake in non-metastatic castration-resistant prostate cancer and expansion into metastatic castration-sensitive settings. More than 200,000 patients have been treated worldwide to date, and regulatory filings are underway in China with approval expected in 2026, underscoring a strong growth trajectory that will materially boost Bayer’s oncology revenues over the next five years.

At the 44th Annual J.P. Morgan Healthcare Conference, Stefan Oelrich, Head of Bayer’s Pharmaceuticals Division, reaffirmed the group’s goal of returning its pharma business to mid-single-digit percentage sales growth no later than 2027. The division targets an operating margin of approximately 30% by 2030, leveraging cost efficiencies from organizational delayering and concentrated investment in high-value launches. In 2025, Bayer secured five pivotal global approvals across oncology, cardiology and women’s health, laying the groundwork for this objectives-driven growth.

Bayer’s pipeline momentum is driven by advanced assets in cardiovascular, renal and immunology. Topline Phase III data from the OCEANIC-STROKE trial of the oral Factor XIa inhibitor asundexian demonstrated both safety and efficacy for secondary stroke prevention, positioning it as the first successful agent in its class. Meanwhile, finerenone (Kerendia®) received U.S. and Japanese approvals for heart-failure patients with left-ventricular ejection fraction ≥ 40%, building on established chronic kidney disease indications. Additional mid-stage programs—ranging from gene therapy for congestive heart failure to first-in-class antibodies for deep vein thrombosis—are set to enter pivotal trials by 2027, underpinning the division’s growth runway.

Beyond prostate cancer, Bayer’s oncology franchise delivered continued momentum in 2025. Following accelerated FDA approval of sevabertinib (Hyrnuo®) for HER2-mutant non-small cell lung cancer, the company has two Phase III readouts for darolutamide in earlier prostate-cancer settings slated for 2027 and 2028. The EORTC PEACE III study of radium-223 dichloride (Xofigo®) combined with enzalutamide met its primary endpoint, with an additional Phase III readout planned in 2026. With over a dozen first-in-class candidates in early development, Bayer is well-positioned to maintain leadership in precision oncology and drive double-digit sales growth in its cancer portfolio.